Fig. 7

Kdm1a regulates AChR gene expression and NMJ functions. A Immunoblot showing the enhancement of H3K4me2 after ORY-1001 injection in TA muscles. B Real-time PCR analysis of synaptic gene expression in TA muscles with the ORY1001 treatment. Three mice per group. t-test. C ChIP assay showing ORY-1001 treatment promotes H3K4me2 to bind with the promoters of AChR subunits. D Whole-mount staining of TA muscles in mice after ORY-1001 injection (Day25). R-BTX (Red); NF (Green). E Mouse grip strength at indicated days after vehicle or ORY-1001 treatment. 11 mice in each group on day 0 and 7. n = 9 mice in control group and n = 10 mice in ORY-1001 group on day 25. Two-way ANOVA with Sidak’s post hoc test for multiple comparisons. Day: F (2,57) = 2.766; treatment F (1,57) = 2.271. F Rotarod analysis at indicated days after vehicle or ORY-1001 treatment. 11 mice in each group on day 0 and 7. 10 mice in each group on day 25. Two-way ANOVA with Sidak’s post hoc test for multiple comparisons. Day: F (2,58) = 4.874; treatment F (1,58) = 16.2. Unless otherwise specified, three independent experiments were performed; the mean ± SEM is shown. *p < 0.05, **p < 0.01, and ***p < 0.001